Quebec Pancreas Cancer Study

Last updated: April 16, 2024
Sponsor: George Zogopoulos
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pancreatic Cancer

Digestive System Neoplasms

Gall Bladder Cancer

Treatment

N/A

Clinical Study ID

NCT04104230
2018-3171
  • Ages > 18
  • All Genders

Study Summary

The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related cancer or a related pre-cancerous condition, and their families.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Individual diagnosed with pancreatic cancer.
  • Individual diagnosed with a related cancer (bile duct cancer, ampullary cancer,duodenal cancer, gallbladder cancer).
  • Individual diagnosed with pancreatic neoplasm or pancreatic cyst.
  • High-risk individuals with Familial Pancreatic Cancer (3 or more relatives affectedwith adenocarcinoma).
  • High-risk individuals with 2 first-degree relatives affected with young-onsetpancreatic adenocarcinoma (≤ 50 years old).
  • High-risk individuals with one of the following Hereditary Cancer Syndromes:Peutz-Jeghers Syndrome (STK11 gene mutation), Familial Atypical Multiple Mole MelanomaSyndrome (CDKN2A gene mutation), or Hereditary Pancreatitis (PRSS1 gene mutation) withclinical manifestations.
  • High-risk individuals with one of the following Hereditary Cancer Syndromes:Hereditary Breast and Ovarian Cancer Syndrome (BRCA1, BRCA2 or PALB2 gene mutation),Lynch Syndrome (MLH1, MSH2, MSH6, PMS2 or EPCAM gene mutation), or Hereditary BreastCancer (ATM gene mutation), WITH a family history of cancer.

Exclusion

Exclusion Criteria:

  • High-risk individuals with one of the following Hereditary Cancer Syndromes:Hereditary Breast and Ovarian Cancer Syndrome (BRCA1, BRCA2 or PALB2 gene mutation),Lynch Syndrome (MLH1, MSH2, MSH6, PMS2 or EPCAM gene mutation), or Hereditary BreastCancer (ATM gene mutation), WITHOUT a family history of cancer.

Study Design

Total Participants: 2000
Study Start date:
March 12, 2012
Estimated Completion Date:
January 31, 2025

Study Description

The objectives of the QPCS are as follows:

  1. To study the epidemiology of pancreas cancer, related cancers and related pre-cancerous conditions, including the risk factors and patient outcomes.

  2. To characterize the contribution of known hereditary cancer syndromes to pancreas cancer, related cancers, and related pre-cancerous conditions.

  3. To identify new genetic and epigenetic changes associated with hereditary pancreas cancer, related cancers, and related pre-cancerous conditions. DNA contains the instructions used in the development and functioning of living organisms, including humans. Epigenetic changes are changes other than changes in the underlying DNA sequence.

  4. To study the tumour biology of pancreas cancer and related pre-cancerous conditions. This may include studying the tumour and the environment surrounding the tumour, as well as blood and/or saliva samples. The studies may include characterization of genetic, genomic, transcriptomic, epigenetic, proteomic, and metabolomic changes.

  5. To identify and characterize biomarkers associated with pancreas cancer, related cancers and related pre-cancerous conditions.

  6. To determine if there are any epidemiological, clinical and outcome (for example, overall survival) associations with the genetic, genomic, epigenetic, transcriptomic, proteomic, metabolomic or other biologic changes that occur in pancreas cancer, related cancers and related pre-cancerous conditions.

Connect with a study center

  • McGill University Health Centre

    Montréal, Quebec H4A 3J1
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.